Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
Equashield II Covers the Most Routes of Exposure; First Product to Prevent Contamination of Syringe Plungers by Hazardous Drugs
PORT WASHINGTON, New York, December 9, 2013 /PRNewswire/ --
Equashield (http://www.equashield.com/), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced the launch of Equashield II, the safest closed drug transfer system for medical professionals. Equashield II, the only solution that prevents contamination of syringe plungers by hazardous drugs, represents a breakthrough in medical occupational safety, specifically for pharmacists and nurses.
"We are proud to unveil our second generation, market-leading solution, Equashield II," said Marino Kriheli, Product Manager for Equashield. "Other products on the market offer medical professionals dealing with chemotherapy and other hazardous drugs partial or no protection. By covering more routes of exposure than ever, this product is a truly closed system, and as such, provides medical professionals with unprecedented safety. With its preassembled unique syringe it is also easier and faster to use than any other system, increasing overall hospital productivity."
Equashield's first generation device was initially deployed in 2010 at Cleveland Clinic, and is currently used in more than 200 hospitals and clinics in the U.S. committed to ensuring the safety of medical professionals and patients.
Equashield II was launched at ASHP's Midyear Clinical Meeting, the largest event for pharmacists and pharmacy professionals in the world. Equashield will be exhibiting at the ASHP Meeting through December 11th and can be visited at booth #707.
Equashield is a leading developer of closed system drug transfer devices that protect healthcare professionals from hazardous drug and vapor exposure. EQUASHIELD® is clinically proven to eliminate surface contamination with antineoplastic agents and prevent microbial ingress, having demonstrated the ability to extend beyond-use dating for single-use or non-preserved drugs. The system consists of a unique syringe with encapsulated barrel and plunger, built-in closed pressure equalization, and an integrated single motion connector that remains free of drug residuals after multiple connections. EQUASHIELD® is the only preassembled syringe on the market that requires no further setup, thereby contributing to ease of use and overall hospital productivity. For more information, visit the company's website at http://www.equashield.com/.
Finn Partners Israel for Equashield
©2012 PR Newswire. All Rights Reserved.